Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)-Reference-Cited by-同舟云学术

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

Published:2014-08-25 Issue:1 Volume:29 Page:20-26
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Barosi G,Tefferi A,Besses C,Birgegard G,Cervantes F,Finazzi G,Gisslinger H,Griesshammer M,Harrison C,Hehlmann R,Hermouet S,Kiladjian J-J,Kröger N,Mesa R,Mc Mullin M F,Pardanani A,Passamonti F,Samuelsson J,Vannucchi A M,Reiter A,Silver R T,Verstovsek S,Tognoni G,Barbui T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014250.pdf

Reference60 articles.

1. Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R et al. RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012; 48: 3257–3266.

2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H (eds) WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008.

3. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methodological challenges in the development of endpoints for myelofibrosis clinical trials;The Lancet Haematology;2024-05

2. Quantitative interpretation of bone marrow biopsies in MPN—What's the point in a molecular age?;British Journal of Haematology;2023-10-19

3. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-26

4. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis;Current Opinion in Hematology;2022-12-29

5. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain;Annals of Hematology;2022-11-23